Compare Heron Therapeutics Inc (HRTX) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Transocean Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Transocean Ltd trades at $5.54 (market cap $6.19B). The key difference: Transocean Ltd is far larger — about 91× Heron Therapeutics Inc's market cap, and Transocean Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Transocean Ltd for 18 Days on average.
| HRTX | RIG | |
|---|---|---|
Market Cap | $68.01M | $6.19B |
Volume | 1,891,941 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $1.49 | $7.58 |
52-Week Low | $0.27 | $3.08 |
Typical Hold Time | 35 Days | 18 Days |
Enterprise Value | $174.75M | $10.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Transocean (RIG) trades at $5.55, up 2.97% on the day, with a bullish technical signal driven by oscillators. The company reported a Q2 2026 EPS beat but remains unprofitable with a net income margin of -40.24%. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract awards, supporting cash flow growth. The stock shows mixed analyst sentiment with a 39.06% buy rating.
The outlook is speculative, hinging on successful deleveraging and offshore cycle strength. Investment opportunity lies in cash flow improvement and backlog execution, but risks include high debt, execution challenges from the Valaris deal, and persistent negative profitability. The stock presents a high-risk, event-driven play for investors betting on an offshore drilling recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
